A Phase 1b/2 Clinical Trial Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AUR103 Calcium in Patients With HER2-positive Advanced Gastric/Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov) - Apr 18, 2026 - P1/2 | N=2 | Terminated | Sponsor: Aurigene Discovery Technologies Limited | N=18 ➔ 2 | Trial completion date: Nov 2028 ➔ Dec 2025 | Recruiting ➔ Terminated | Trial primary completion date: Nov 2027 ➔ Dec 2025; Patient recruitment problems.
Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Esophageal Cancer • Gastric Cancer • Gastroesophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor • HER-2
|